Keratoacanthoma - Keratoakantoom
☆ Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
Tüüpiline Keratoakantoom (Keratoacanthoma)
References
Keratoacanthoma (KA) on sagedane nahakasvaja, mis on tuntud oma kiire kasvu ja iseseisva taandumisvõime poolest. Tavaliselt esineb see vanematel heledanahalistel meestel, kellel on anamneesis päikesekahjustusi. Kuigi kirurgiline eemaldamine ekstsisiooni või Mohsi mikrograafilise kirurgia abil on tavaline ravi, on saadaval mitmeid muid ravivõimalusi.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) on madala astme kasvaja, mis saab alguse teatud naha näärmetest ja näeb mikroskoobi all välja sarnane kasvajaga squamous cell carcinoma (SCC) . Käimas on arutelu selle üle, kas KA tuleks klassifitseerida invasiivse SCC vormiks.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) on levinuim vähitüüp inimestel, eriti vanemate inimeste seas. Operatsiooni kasutatakse tavaliselt cSCC raviks, kuid mõne patsiendi puhul, kes ei saa operatsiooni teha või otsustab seda mitte teha, võib kaaluda muid võimalusi, nagu kahjustuse seesisene ravi. Kasutatud on traditsioonilisi kahjustusesiseseid ravimeetodeid (methotrexate or 5-fluorouracil) , kuid käimas on uuringud selliste uute lähenemisviiside kohta nagu kahjustusesisene immunoteraapia ja onkolüütiline viroteraapia. Siin vaatleme erinevaid cSCC intralesionaalseid ravimeetodeid, alates klassikalistest meetoditest kuni tipptasemel strateegiateni.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Mikroskoobi all sarnaneb keratoakantoom (keratoacanthoma) väga lamerakk-kartsinoomiga. Kuigi mõned patoloogid klassifitseerivad keratoakantoom (keratoacanthoma) eraldiseisvaks üksuseks, mitte pahaloomuliseks kasvajaks, areneb ligikaudu 6% kliinilistest ja histoloogilistest keratoakantoom (keratoacanthoma) invasiivseks ja agressiivseks lamerakuliseks vähiks.
○ Diagnostika ja ravi
#Dermoscopy
#Skin biopsy